Analytical methods for the detection of PD-1/PD-L1 and other molecules related to immune checkpoints

Wang, Pei; Tang, Longfei; Zhou, Bohui; Cheng, Liangfen; Zhao, Robert Chunhua; Zhang, Juan

doi:10.1016/j.trac.2021.116505

Cited by 3 publications

(3 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, although monitoring exosomal PD-L1 dynamics can improve the prediction performance, it is time-consuming and may delay the search for alternative treatments for nonresponders. This suggests that the prediction performance of biomarkers should be improved by means of including the joint detection of coexpressed molecules and the exploitation of superior sensing strategies …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Homogeneous, Simple, and Direct Analysis of Exosomal PD-L1 via Aptamer-Bivalent-Cholesterol-Anchor Assembly of DNAzyme (ABCzyme) for Tumor Immunotherapy

et al. 2023

View full text Add to dashboard Cite

Breakthroughs in immune checkpoint inhibitor (ICI) therapy have revolutionized clinical tumor therapy. Immunohistochemistry (IHC) analysis of PD-L1 in tumor tissue has been used to predict the response to tumor immunotherapy, but the results are not reproducible, and IHC is invasive and cannot be used to monitor the dynamic changes in PD-L1 expression during treatment. Monitoring the expression level of the PD-L1 protein on exosomes (exosomal PD-L1) is promising for both tumor diagnosis and tumor immunotherapy. Here, we established an aptamer-bivalent-cholesterol-anchor assembly of DNAzyme (ABCzyme) analytical strategy that can directly detect exosomal PD-L1 with a minimum lower limit of detection of 5.21 pg/ mL. In this way, we found that the levels of exosomal PD-L1 are significantly elevated in the peripheral blood of patients with progressive disease. The precise analysis of exosomal PD-L1 by the proposed ABCzyme strategy provides a potentially convenient method for the dynamic monitoring of tumor progression in patients who receive immunotherapy and proves to be a potential and effective liquid biopsy method for tumor immunotherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

“…This suggests that the prediction performance of biomarkers should be improved by means of including the joint detection of coexpressed molecules and the exploitation of superior sensing strategies. 39 ■ CONCLUSIONS…”

Section: ■ Introductionmentioning

confidence: 99%

Homogeneous, Simple, and Direct Analysis of Exosomal PD-L1 via Aptamer-Bivalent-Cholesterol-Anchor Assembly of DNAzyme (ABCzyme) for Tumor Immunotherapy

et al. 2023

View full text Add to dashboard Cite

show abstract

“… 4 The conventional methods for immune checkpoint detection include immunohistochemistry (IHC), western blot (WB), enzyme linked immunosorbent assay (ELISA), and so on. 5 However, all of aforementioned technologies require tissue sample collection, which can be time consuming while introducing pain and risk to patients. It is most important to develop new noninvasive, dynamic, and quantitative technologies for whole-body imaging to map the spatiotemporal heterogeneity of PD-L1 expression.…”

Section: Introductionmentioning

confidence: 99%

Gold nanorods with iron oxide dual-modal bioprobes in SERS-MRI enable accurate programmed cell death ligand-1 expression detection in triple-negative breast cancer

Pan

Zhang

et al. 2023

APL Bioengineering

View full text Add to dashboard Cite

The efficiency of immunotherapy for triple-negative breast cancer (TNBC) is relatively low due to the difficulty in accurately detecting immune checkpoints. The detection of TNBC-related programmed cell death ligand-1 (PD-L1) expression is important to guide immunotherapy and improve treatment efficiency. Surface-enhanced Raman spectroscopy (SERS) and magnetic resonance (MR) imaging exhibit great potential for early TNBC diagnosis. SERS, an optical imaging mode, has the advantages of high detection sensitivity, good spatial resolution, and “fingerprint” spectral characteristics; however, the shallow detection penetration of SERS bioprobes limits its application in vivo. MR has the advantages of allowing deep penetration with no radiation; however, its spatial resolution needs to be improved. SERS and MR have complementary imaging features for tumor marker detection. In this study, gold nanorod and ultrasmall iron oxide nanoparticle composites were developed as dual-modal bioprobes for SERS-MRI to detect PD-L1 expression. Anti-PD-L1 (aPD-L1) was utilized to improve the targeting ability and specificity of PD-L1 expression detection. TNBC cells expressing PD-L1 were accurately detected via the SERS imaging mode in vitro, which can image at the single-cell level. In addition, bioprobe accumulation in PD-L1 expression-related tumor-bearing mice was simply and dynamically monitored and analyzed in vivo using MR and SERS. To the best of our knowledge, this is the first time a SERS-MRI dual-modal bioprobe combined with a PD-L1 antibody has been successfully used to detect PD-L1 expression in TNBC. This work paves the way for the design of high-performance bioprobe-based contrast agents for the clinical immunotherapy of TNBC.

show abstract

Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseases

Bailly

Thuru

Goossens

et al. 2023

Biochemical Pharmacology

View full text Add to dashboard Cite

Analytical methods for the detection of PD-1/PD-L1 and other molecules related to immune checkpoints

Cited by 3 publications

References 93 publications

Homogeneous, Simple, and Direct Analysis of Exosomal PD-L1 via Aptamer-Bivalent-Cholesterol-Anchor Assembly of DNAzyme (ABCzyme) for Tumor Immunotherapy

Homogeneous, Simple, and Direct Analysis of Exosomal PD-L1 via Aptamer-Bivalent-Cholesterol-Anchor Assembly of DNAzyme (ABCzyme) for Tumor Immunotherapy

Gold nanorods with iron oxide dual-modal bioprobes in SERS-MRI enable accurate programmed cell death ligand-1 expression detection in triple-negative breast cancer

Soluble TIM-3 as a biomarker of progression and therapeutic response in cancers and other of human diseases

Contact Info

Product

Resources

About